FDA And CMS Draft Gene Therapy Framework To Add Patient-Specific Variants Without New Trials

The FDA on Tuesday released draft guidance intended to speed development and approval of personalized gene therapies for rare diseases, including ultra-rare conditions where traditional trial models are often impractical. The document, issued as part of a broader push from the Department of Health and Human Services that also includes CMS, lays out how sponsors could structure a single biologics license application to cover multiple patient-specific product variants.

At the center of the framework is what the agencies call the Individualized Feature Space, or IFS. The idea is to define in advance how a gene therapy can vary from patient to patient while still remaining within the scope of one BLA. According to the joint release cited by BioSpace, when a new patient-specific variant falls within those boundaries and assays show adequate safety and activity, sponsors can submit it to the BLA without needing to perform additional clinical trials.

That is the main market signal in the draft: the FDA is trying to convert one-off or highly customized therapies from scientific exceptions into products that can fit a repeatable regulatory structure. For developers working in very small populations, the value is not only faster review but a clearer path to scaling an individualized platform across multiple mutations without reopening the clinical package each time.

The policy shift

CBER Director Karim Mikhail said the guidance is meant to provide “a clear and scientifically rigorous framework for BLA submission and postapproval management” of these therapies. Beyond the IFS concept, the document also addresses manufacturing, safety testing and labeling, all of which have been persistent friction points for gene therapy programs.

The draft builds on recent FDA rare disease actions rather than standing alone. BioSpace said it follows the Plausible Mechanism Pathway announced by former Commissioner Marty Makary and former CBER director Vinay Prasad in November last year. That pathway was intended to expedite therapies for diseases affecting exceedingly small patient populations where randomized trials are not feasible. Makary and Prasad pointed in a Nov. 13, 2025 New England Journal of Medicine article to Baby KJ, a child with CPS1 deficiency treated with a single-use CRISPR therapy produced specifically for him, as an example of the pathway’s intent.

The latest guidance also arrived less than two weeks after the FDA introduced its Rare Disease Framework Initiative, which is meant to standardize how the agency evaluates scientific evidence in rare disease and bring therapies to patients faster. RBC Capital Markets analysts attending the National Organization for Rare Diseases Breakthrough Summit in Washington, D.C., wrote that they came away incrementally more positive on the rare disease regulatory setup, citing a constructive tone from Mikhail and Michael Davis and a desire to harmonize regulatory standards across the two divisions to increase predictability for sponsors.

Access and reimbursement

CMS used the same announcement to stress that faster approval will not matter much if patients cannot obtain the therapies. CMS Administrator Mehmet Oz said in the press release that a medical breakthrough only matters if patients can get it, and said CMS is bringing state Medicaid programs together to negotiate with drug manufacturers.

That effort builds on the Cell and Gene Therapy Access Model introduced in January 2024, a voluntary initiative under which CMS negotiates voluntary outcomes-based agreements on behalf of state Medicaid programs for cell and gene therapies. The model initially focused on gene therapies for sickle cell disease, and in December that year Vertex Pharmaceuticals and bluebird bio joined with Casgevy and Lyfgenia, respectively.

On Tuesday, CMS said it would broaden the model beyond sickle cell disease. In the coming months, the agency plans to release a Request for Applications for manufacturers designed to expand the model’s scope and enable negotiations to begin sooner after a therapy receives FDA approval or licensure, while also accepting applications for therapies that are already approved or licensed.

Taken together, the FDA and CMS moves suggest the administration is trying to de-risk two separate bottlenecks at once: how personalized gene therapies are reviewed and how expensive products reach Medicaid patients after approval. If the draft guidance survives into final policy with its core structure intact, it could make individualized rare disease programs more investable by giving sponsors a clearer route to both licensure and postapproval expansion.